Our data suggested that an antibody type drug targeting ULBP1 or ULBP2/5/6 might be appropriate for the treatment of squamous cell carcinoma whereas one targeting ULBP4 might be useful for treating adenocarcinoma, as more than a half of studied tumors expressed each of these molecules, respectively. Here, ULBP1 is linked to adenocarcinoma.